{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T03:09:29Z","timestamp":1767409769808,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21nf0101621"],"award-info":[{"award-number":["JP21nf0101621"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.vaccine.2022.02.030","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T15:52:20Z","timestamp":1644335540000},"page":"2044-2052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A phase 1\/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report"],"prefix":"10.1016","volume":"40","author":[{"given":"Taisei","family":"Masuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenkichi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sakui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron","family":"Philip Schuring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.vaccine.2022.02.030_b0015","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2022.02.030_b0020","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.02.030_b0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.02.030_b0030","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2022.02.030_b0035","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2022.02.030_b0040","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.02.030_b0050","doi-asserted-by":"crossref","first-page":"n74","DOI":"10.1136\/bmj.n74","article-title":"Covid-19: UK approves Moderna vaccine to be given as two doses 28 days apart","volume":"372","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.vaccine.2022.02.030_b0075","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3390\/vaccines9111321","article-title":"Association between COVID-19 vaccine side effects and body mass index in Spain","volume":"9","author":"Iguacel","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"13","key":"10.1016\/j.vaccine.2022.02.030_b0080","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMc2102131","article-title":"Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2","volume":"384","author":"Blumenthal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.02.030_b0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.02.030_b0090","doi-asserted-by":"crossref","first-page":"n1943","DOI":"10.1136\/bmj.n1943","article-title":"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ."},{"issue":"9","key":"10.1016\/j.vaccine.2022.02.030_b0095","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/s41591-021-01446-y","article-title":"mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar","volume":"27","author":"Chemaitelly","year":"2021","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22001645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:09:01Z","timestamp":1759403341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22001645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":12,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0264410X22001645"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 1\/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}